Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2002, p. 2588-2594, Vol. 46, No. 8
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.8.2588-2594.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Laboratoire de Parasitologie, Hygiène et Zoologie, Faculté de Pharmacie, Université d'Aix-Marseille II, Marseille Cedex 05,1 Laboratoire de Valorisation de la Chimie Fine, Université d'Aix-Marseille III, Marseille Cedex 20, France2
Received 13 February 2002/ Returned for modification 10 April 2002/ Accepted 14 May 2002
|
|
|---|
|
|
|---|
Benzothiazoles comprise a novel class of therapeutic compounds shown to exert a wide range of biological activities. Initially employed as pigments in leather tanning, most of the compounds that exhibited both high levels of fluorescence properties and a capacity to bind with cellular structures were extensively used as fluorochromes. Since the 1990s, various pharmacological investigations of newly synthesized benzothiazole derivatives demonstrated interesting pharmacological activities and led to the development of new medications for treating human diseases. Among the most efficient compounds, riluzole, sulfathiazole, mercapto-2-benzothiazole, and 2-(phenylsulfonyl)-benzothiazole revealed neuroprotective (1, 12), anticonvulsive (14), antiallergenic, and antimicrobial (7, 11, 19) activities, respectively, while other derivatives such as 2-(4-aminophenyl)-benzothiazoles exhibited potent antitumoral activity (3, 5), probably due to their capacity to bind with tumor-specific proteins. In contrast to other anticancer drugs, such as acridines, that have been extensively studied for their antileishmanial (8) and trypanocidal activities (8), benzothiazoles have been poorly investigated. Nevertheless, their potent capacity to interfere with cellular structures suggested that they are candidates for activity against protozoa. On this basis, we synthesized position 2 substitution-bearing 6-nitro- and 6-amino-benzothiazoles and their corresponding anthranilic acids and assessed the in vitro antiproliferative activity of each derivative against parasites of the genus Leishmania compared to its activity against another protozoan parasite, such as Trichomonas vaginalis, and its toxicity against human monocytes.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Physicochemical properties and predictive values of biological activities calculated for position 2 substitution-bearing 6-nitro and 6-amino-benzothiazoles and their corresponding anthranilic acids
|
Activity against Trichomonas vaginalis. Parasites were maintained in continuous culture in the Trichomonas medium TM 161 (Oxoid) supplemented with 8% heat-inactivated horse serum (Eurobio, Paris, France). Parasites in late log phase were incubated at an average of 104 cells/ml, and a range of benzothiazole concentrations were aseptically incorporated into duplicate cultures (final DMSO concentration, less than 5%). Negative controls treated by solvent (DMSO) and positive controls containing a range of metronidazole (Sigma) concentrations were added to each set of experiments. After a 48-h incubation period at 37°C, viable parasites were identified and counted microscopically on the basis of their aspect and motility and 50% inhibitory concentration (IC50) values were determined.
Antileishmanial activity against promastigotes. Leishmania infantum promastigotes in late log phase were incubated in RPMI medium supplemented with 12% fetal calf serum at an average of 105 cells/ml, and a range of benzothiazole concentrations were aseptically incorporated into duplicate cultures (final DMSO concentration, less than 5%). Following a 48-h incubation period at 25°C, promastigote growth was estimated by counting parasites with a hemacytometer and IC50 values were determined.
Antileishmanial activity against intracellular amastigotes. Intracellular amastigote culturing was performed in human monocyte-derived macrophages according to the methodology previously described by Ogunkolade et al. (15). Maturation of monocytes into adherent macrophages was induced by treating exponentially growing monocytes (105 cells/ml) with 1 µM phorbol myristate acetate (Sigma). After a 48-h incubation period at 37°C (5% CO2) in chamber slides (Fisher, Paris, France), cells were rinsed with fresh medium and suspended in RPMI medium containing stationary-phase promastigotes (cell/promastigote ratio, 1/10). After a 24-h incubation period at 37°C (5% CO2), promastigotes were removed by four successive washes with fresh medium. Adapted dilutions of chemical compounds were added in duplicate chambers, and cultures were incubated for 96 h at 37°C (5% CO2). Negative controls treated by solvent (DMSO) and positive controls containing a range of amphotericin B (Sigma) concentrations were added to each set of experiments. At the end of the incubation period, cells were harvested with analytical-grade methanol (Sigma) and stained with 10% Giemsa stain (Eurobio). The percentage of infected macrophages in each assay was determined microscopically at magnification of x1,000, and IC50 values for the infected macrophages were determined.
Toxicity against human monocytes. In vitro toxicity of benzothiazoles was assessed for human monocytes maintained in RPMI medium (Eurobio) supplemented with 10% fetal calf serum (Eurobio) at 37°C in 5% CO2 and replicated every 7 days. A range of benzothiazole concentrations were incorporated in late- log-phase monocytes (105 cells/ml), and cultures were incubated at 37°C with 5% CO2. After a 72-h incubation period, cell growth and viability were measured by flow cytometry after staining monocytes with propidium iodide (1 µM final concentration in culture medium). IC50 values and 50% lethal concentration (LC50) values were determined for cell growth and viability, respectively. An in vitro selective index (SI) value, corresponding to the ratio between antiparasitic and cytotoxic activities, was calculated for each parasite according to the following formula: SI = LC50 against human monocytes/IC50 against intracellular amastigotes or SI = LC50 against human monocytes/IC50 against T. vaginalis.
Toxicity of compound C11 against promastigotes and extracellular amastigotes. Promastigotes were incubated in RPMI medium supplemented with 12% fetal calf serum and incubated at 25°C. Amastigotes were obtained from human macrophages previously infected with promastigotes according to the protocol described by Ogunkolade et al. (15). They were transferred into RPMI medium supplemented with 20% fetal calf serum, titers were determined at pH 5.5, and the mixture was incubated at 37°C (5% CO2). Under these conditions, extracellular amastigotes could be maintained for more than 1 week. Various concentrations of compound C11 were aseptically incorporated into duplicate promastigote and extracellular amastigote cultures and incubated at 25 and 37°C, respectively. Following a 48-h incubation period, parasite viability was estimated by flow cytometry after staining with 1 µM propidium iodide.
Effect of compound C11 on nitric oxide production.
Maturation of human monocytes into adherent macrophages was induced by treating exponentially growing monocytes (105 cells/ml) with 1 µM phorbol myristate acetate (Sigma). After a 48-h incubation period at 37°C (5% CO2) in chamber slides (Fisher), cells were rinsed with fresh medium and suspended in RPMI medium containing various concentrations of compound C11, in the presence or absence of 10 U of human recombinant gamma interferon (IFN
)/ml. After 48 h at 37°C, NO production was measured by assessing the nitrite content of culture supernatants by the method described by Ding et al. (6). Fresh Griess reagent (100 µl) was added to equal volumes of culture supernatants, and the optical density at 540 nm was measured after 15 min of incubation at room temperature. Nitrite concentrations were determined using NaNO2 diluted in Dulbecco's modified Eagle's medium as the standard.
Effect of compound C11 on phagocytic capacities of human macrophages. Assays were performed on human monocyte-derived macrophages. Maturation of monocytes into adherent macrophages was performed by treating exponentially growing monocytes (105 cells/ml) with 1 µM phorbol myristate acetate (Sigma). After a 48-h incubation period at 37°C (5% CO2) in chamber slides (Fisher), cells were rinsed with fresh medium and various concentrations of compound C11 were incorporated into duplicate cultures. After a 48-h incubation period at 37°C, cells were rinsed with fresh medium and infected with RPMI medium containing stationary-phase promastigotes (cell/promastigote ratio, 1/10). After a 4-h incubation period at 37°C (5% CO2), promastigotes were removed by four successive washes with fresh medium, fixed with methanol, and stained with 10% Giemsa stain. The percentage of macrophages containing adherent or intracellular parasites was analyzed microscopically at a magnification of x1,000.
|
|
|---|
Table 2 presents the results of comparisons of in vitro antiprotozoal activities to toxicity against human monocytes. Results obtained on human cells clearly demonstrated that benzothiazoles and anthranilic acids displayed weak toxicity, since most of the LC50 values appeared to be >100 µM. Data concerning antiproliferative properties revealed that various compounds could inhibit the growth of transformed cells. This antiproliferative activity was mainly observed for 6-nitro-benzothiazoles bearing a phenylenediamino group in position 2 and for 6-amino-benzothiazoles bearing an amino or dimethylamino group in position 2. Moreover, the experiments using compounds A6, B6, and C6 demonstrated that the presence of a replacement piperidino group in position 2 was responsible for the antiproliferative activity of both molecular structures.
|
View this table: [in a new window] |
TABLE 2. Toxicity and antiparasitic activity of benzothiazole and anthranilic acid derivatives
|
Antileishmanial activity was explored for both extracellular promastigote and intracellular amastigote forms. The results displayed in Table 2 show that most benzothiazoles and anthranilic acids were able to inhibit promastigote growth; however, IC50s differed considerably according to the chemical nature of the replacement group in position 2. Values obtained for intracellular amastigotes demonstrated that various compounds could also inhibit parasite growth inside parasitophorous vacuoles. The results also revealed that 6-nitro-benzothiazoles and anthranilic acids appeared to exhibit more efficient activity than 6-amino-benzothiazoles. Five compounds (A7, A13, B4, C6, and C11) displayed potent antileishmanial activity, with IC50s lower than 10 µM; however, only compounds B4, C3, and C11, which showed weak toxicity against human cells, exhibited interesting pharmacological selectivity, with SI values greater than 50. These three compounds were far less efficient with respect to activity levels for the promastigote form of the parasite, suggesting that their antileishmanial action could be associated with inhibition of amastigote-specific biochemical pathways or modulation of cell-mediated response.
On this basis, additional experiments, which included measurement of extracellular amastigote viability, macrophage-dependent NO production, and modulation of phagocytic properties, were conducted with compound C11 to explore possible mechanisms of action. The results for assays of toxicity against axenic amastigotes and promastigotes are presented in Fig. 1. These results show that compound C11 induced a dose-dependent decrease of parasite viability in both parasitic forms (LC50s of 44.7 and 31.6 µM in promastigotes and axenic amastigotes, respectively) and indicate that C11-related antileishmanial action was not dependent on the developmental stage of the parasite. Effects of the presence of compound C11 on macrophage phagocytic properties are presented in Fig. 2. A significant dose-dependent decrease of phagocytic activity could be observed at concentrations seen to result in reduced toxicity against human cells, suggesting that compound C11 could prevent the appearance of the internalization mechanisms that occur in Leishmania infection. Effects of compound C11 on NO production are presented in Fig. 3. A weak drug-related NO release was observed in macrophages incubated without IFN-
, while a twofold increase of NO content was determined in supernatants of macrophages incubated with IFN-
. These results suggest that compound C11 interferes with host-protective mechanisms against Leishmania by stimulating NO production according to a mechanism synergistically enhanced by the presence of IFN-
.
![]() View larger version (18K): [in a new window] |
FIG. 1. Effects of compound C11 on the viability of axenic amastigotes and promastigotes.
|
![]() View larger version (16K): [in a new window] |
FIG. 2. Effects of compound C11 on the phagocytic capacities of human macrophages.
|
![]() View larger version (17K): [in a new window] |
FIG. 3. Effects of compound C11 on NO production by human macrophages.
|
|
|
|---|
6-Nitro-benzothiazoles (compounds A1 to A13) displayed interesting predictive values for antitrichomonal activities. Probably due to the presence of levels of 6-nitro known to play an important role in the toxicity of metronidazole against Trichomonas, these values were not confirmed by experimental data, since all IC50s except those of compound A1 were higher than 10 µM. They indicated that antitrichomonal properties depended greatly on the nature of the replacement group at position 2; on this basis of this finding, association of 6-nitro and 2-chloro groups was shown to enhance toxicity against T. vaginalis. As expected, this antitrichomonal property was associated with increased antiproliferative activity against human cells (IC50 = 4.5 µM). Concerning antileishmanial activity, various 6-nitro-benzothiazoles presented interesting predictive biological values, especially compound A7 (bearing a 2-N-diethylamine-propylamino group). This group obtained a predictive Pa value higher than 0.8, indicating that its chemical structure was closely similar to those of known antileishmanial drugs. Experimental results confirmed that the presence of the 2-N-diethylamine-propylamino group was responsible for antileishmanial activity of 6-nitro-benzothiazoles (IC50 = 8.1 µM, SI = 31.8); nevertheless, the results also demonstrated that this property disappeared when the 6-nitro group was reduced into a 6-amino group (IC50 = 117.2 µM, SI = 1.5).
6-Amino-benzothiazoles exhibited weak predictive biological values, suggesting that their chemical structures were highly different from those of known active compounds. Experimental data confirmed these values, showing that 6-amino-benzothiazoles were poorly effective at inhibiting the growth of T. vaginalis and L. infantum. Nevertheless, compound B4, bearing a replacement N-dimethylamino group at position 2, exhibited an interesting antileishmanial effect (IC50 = 2.4 µM, SI = 53.8). Interestingly, compounds B3 and B5, bearing 2-N-amino and 2-N-diethylamino groups, respectively, appeared far less active, suggesting that conformational properties could play an important role in antiparasitic activity.
Anthranilic acids displayed low predictive biological values; nevertheless, most of these derivatives exhibited antitrichomonal and antileishmanial effects. Compound C5, bearing a 2-N-diethylamino group, exerted significant selective antitrichomonal activity (IC50 = 2.9 µM, SI = 48.8), while compound C11, bearing a 2-ethanolamino group, exhibited a potent selective antileishmanial action (IC50 = 2.5 µM, SI = 231). This effect was highly specific for the intracellular amastigote stage of the parasite, since weak toxicity could be observed against the promastigote and the extracellular axenic amastigote forms, suggesting that the molecule could modulate host-specific mechanisms. Additional experiments confirmed this hypothesis, since they demonstrated that compound C11 could protect human macrophages from Leishmania parasitism by two different mechanisms: reduction of parasite internalization by inhibition of macrophage phagocytosis and killing of intracellular amastigotes by enhanced NO production.
In mammals, Leishmania multiply almost exclusively as amastigotes inside cells of the mononuclear phagocytic system. After the mammal has been inoculated with infective promastigotes by the bite of a parasite-carrying sand fly through the dermis, the binding of the parasites to the macrophage cell surface occurs through numerous receptors. In physiological conditions, the main receptors appear to be complement receptor type I (CR1) and CR3 (17). Moreover, although some active participation of the parasite in host-cell entry cannot be completely excluded, it is generally accepted that phagocytosis is the basic mechanism for endocytosis of Leishmania (2, 17). Immediately following phagocytosis, Leishmania are located in compartments that are delimited by membrane originating from the macrophage plasmalemma. Survival of Leishmania parasites within the mammalian host has been shown to depend greatly on the capacity for the parasite to adhere and internalize into resident or recruited macrophages. On this basis, chemically induced modulation of macrophage phagocytic properties could influence parasite infection, and various compounds, including oxidant molecules and neuropeptides, demonstrated in vivo antileishmanial activities along with inhibition of macrophage phagocytosis (17).
Within the parasitophorous vacuole, the promastigotes are transformed into aflagellated amastigote forms which multiply asexually in resting macrophages and, after rupture of the parasitized cells, disseminate to the other cells of the reticuloendothelial system (2). However, macrophages may prevent parasite development by using protective mechanisms for killing intracellular amastigotes. Among these mechanisms, production of NO by inducible NO synthase has been shown to represent an essential way of inducing the intracellular destruction of amastigotes (4). Based on these lines of evidence, new techniques using NO-generating compounds have been envisaged for the treatment of human infection and have given encouraging results (4).
Compound C11, which produced a 50% decrease of parasite internalization and a twofold increase of NO production in activated macrophages, can be considered a promising member of this new class of protective drugs. On this basis, experiments should be completed using new chemical syntheses in order to explore the role of each radical on toxicity and antiparasitic or protective abilities and a complete evaluation of biological effects should be performed by in vivo assays of rodents infected with L. infantum.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»